Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. A. Jansson, J. Rocklöv, A. Lindberg, B. Forsberg, J. Björkman, E. Rönmark, B. Lundbäck (Stockholm, Umeå, Luleå, Gothenburg, Sweden). An increase of 1%-predicted in FEV₁ considerably saves costs for COPD. Eur Respir J 2008; 32: Suppl. 52, 1155

Member's Comments

No comment yet.

Related content which might interest you: Frequent exacerbations in COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Regular follow-up in severe asthma may reduce the rate of exacerbations and the FEV1 decline Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 The costs of exacerbations in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 273s Year: 2001 Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 ICS withdrawal and rate of FEV1 decline in a primary care COPD population in England Source: Virtual Congress 2021 – New evidence from longitudinal COPD cohorts and other key studies Year: 2021 Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 The effect of tiotropium on exacerbations and airflow in patients with COPD Source: Eur Respir J 2006; 27: 547-555 Year: 2006 Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD Source: Eur Respir J, 57 (3) 2004008; 10.1183/13993003.04008-2020 Year: 2021 Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2005; 26: Suppl. 49, 510s Year: 2005 Individual decline of FEV1 show diversity in COPD Source: Annual Congress 2012 - Environmental exposure and other risk factors for airway diseases Year: 2012 Improvements in inspiratory capacity with tiotropium in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 491s Year: 2002 Budesonide results in savings in total costs in mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 237s Year: 2001 Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 The correlation of annual rate of FEV1 decline with the temperature of expired air in COPD patients Source: Annual Congress 2008 - Prognosis in COPD Year: 2008 FEV1/Height2 could be a better alternative than FEV1 in predicting all cause mortality in patients with COPD Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Tiotropium reduces health resource utilization associated with COPD exacerbations Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004 Evaluation of costs of inhospital treatment of COPD exacerbations Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004 The prevalence, the incidence and the cost of COPD exacerbations Source: Annual Congress 2011 - Epidemiology of COPD exacerbations Year: 2011